SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is caught in a broader AI-chip selloff as traders worry that calls for tighter AI regulation could slow data-center expansion and weaken future memory demand; community discussion also points to a reported Taiwan plant work stoppage tied to a labor dispute. Bulls view the drop as an overreaction given strong AI-memory demand, while bears warn that spending or memory pricing could peak.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is under pressure amid a broader AI-chip selloff, as traders worry that tighter AI rules and data-center permitting hurdles could slow infrastructure spending; concerns about debt and circular financing in the AI buildout add to doubts about demand sustainability. The community is divided between dip buyers who expect AI demand to persist or shift elsewhere and bears who see a possible capex-driven bubble.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavaxs Q3 update and sharply higher 2026 revenue outlook, supported by a milestone from Sanofis Phase 3 flu-COVID combination trial, are driving attention. Traders welcomed the improved outlook and leaner operations, while skeptics said revenue remains heavily dependent on Sanofi and wanted new partnerships or concrete oncology and MTA updates.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Concerns that Democratic control could bring tighter AI and data-center rules and slow future buildouts have pressured SNDK alongside other memory and semiconductor stocks. Traders are split between viewing the selloff as an overreaction given earnings and memory demand, and worrying about weaker AI infrastructure spending, cyclical pricing pressure, and further downside.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention amid a sharp semiconductor selloff, with traders pointing to fears that Democratic control could constrain AI and data-center expansion, alongside weak reactions to chip-sector reports and concerns about an AI bubble. The community is split between expecting further losses and viewing the heavy selling as capitulation and a dip-buying opportunity.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snaps quarterly report missed revenue and daily-active-user expectations, with sluggish advertising growth weighing on shares despite improved profitability and a stronger outlook. Traders are split between optimism about cash flow and subscriptions and concerns that weak user and ad trendsand the planned shift from DAU to MAU reportingobscure the core businesss momentum.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins record third-quarter results, stronger-than-expected outlook, and expanded buyback are driving attention, with traders crediting improvements in its AI-powered advertising business for the strong report. Bulls are celebrating the sharp rally, while others warn that growth may moderate and the gains could fade.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is drawing attention after Q3 results beat expectations, led by strong Alani Nu growth and international sales. Traders are weighing that strength against declining revenue for the core Celsius brand and sharply lower gross margins, leaving debate over whether the beat can sustain a recovery.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomms earnings report beat modestly, but a sharp decline in handset revenue and margin pressure from rising component costs overshadowed the results and cautious earnings outlook, prompting a steep post-report selloff. Traders are debating whether growth in automotive, data center and other non-handset businesses can offset the weakness in its smartphone business.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arms quarterly results beat headline expectations, but softer royalty revenue and a largely in-line outlook have overshadowed strong licensing growth and weighed on the shares. Traders are split between buying the dip on AI and data-center demand and questioning whether recurring royalty growth and the companys valuation justify the premium amid weakness in chip stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

Jaguar Health (NASDAQ:JAGX) stock moved upwards by 34.0% to $6.34 during Tuesday's pre-market session. The company's market cap stands at $2.4 million.
Option Care Health (NASDAQ:OPCH) stock roseread more...

Jaguar Health (JAGX) Stock Climbs Over 34% After-Hours: What's Going On?

Jaguar Health shares surged 34.67% after hours Monday following the company's special dividend announcement and debt-payment extensions.read more...

Catalysts Remain in Focus as Investors Hunt Next Big Move

The market is serving up a similar mix of names as Jaguar Health (NASDAQ:JAGX), NeOnc Technologies Holdings (NASDAQ:NTHI), Greenland Mines (NASDAQ:GRML), Beneficient (NASDAQ:BENF) and Apimeds Pharmaceuticals (NYSEAMERICAN:APUS) all had major catalysts this week, while INLIF LIMITED (NASDAQ:INLF) is the only new name to today’s list.

Jaguar Health Stock Surges Friday: What's Happening?

Jaguar Health is surging Friday after announcing debt-for-equity exchanges that cut debt by over $6.7 million and retired a promissory note.read more...

Jaguar Health Stock Slides Thursday: What's Happening?

Jaguar Health shares are sliding Thursday as equity dilution concerns weigh on the company following a debt-for-equity exchange.read more...

Jaguar Health Stock Plunges Wednesday: What's Happening?

Jaguar Health shares are plunging Wednesday morning as profit-taking reverses an explosive Tuesday rally sparked by regulatory fee waivers.read more...

InnovAge, Voyager Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. futures edged higher; InnovAge fell 9.4% after a 10M-share offering. Jaguar Health, Voyager Technologies and other stocks also dropped premarket.read more...

Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket

Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.read more...

JAGX Stock Soars Over 10% Premarket After Best Day In Over 8 Years: What’s Driving The Surge?

Equity

Jaguar Health aims to file for approval of its Crofelemer powder treatment for pediatric MVID in mid-2027.

Jaguar Health Stock Surged 1200% on Tuesday: Here's Why JAGX Stock Is Trending After Hours

Jaguar Health shares jumped 5.19% after hours following FDA fee waivers for two of its commercialized therapies.read more...

This account has been verified as an official JAGX representative.

Verified Account

Jagaur Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the following segments: Animal Health and Human Health. The Animal Health segment is focused on development and commercialization of prescription and non-prescription products for companion and production animals. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Jaguar Health Inc

Bearish Sentiment

<ul class="summary-bullets"><li>JAGX's latest rally followed a 1-for-15 reverse split that took effect last week to support Nasdaq compliance.</li><li>The FDA waived fiscal 2027 fees for Mytesi, an HIV-related diarrhea drug, and Canalevia-CA1, a treatment for chemotherapy-induced diarrhea in dogs.</li><li>All randomized children in Jaguar’s MVID trial are continuing into an extension phase.</li></ul>Shares of Jaguar Health (JAGX)&nbsp;soared&nbsp;11% in premarket trading on Wednesday&nbsp;following their best session in over eight years as FDA fee waivers for two drugs and a surge in retail interest put&nbsp;the commercial-stage pharmaceutical company’s rare-disease plans in focus.<a href="https://stocktwits.com/symbol/JAGX">JAGX stock</a> closed Tuesday at $34.46,&nbsp;rocketing 1,191%, less than a week after a 1-for-15 reverse stock split took effect to support compliance with Nasdaq’s listing standards.<h2 class="st-heading-2">What The FDA Waived For Jaguar</h2>Jaguar said on Tuesday that the FDA waived its fiscal 2027 program fee for Mytesi, an approved treatment for noninfectious diarrhea in adults with HIV/AIDS taking antiretroviral therapy. The agency’s Center for Veterinary Medicine separately waived the fiscal 2027 fee for Canalevia-CA1, a conditionally approved treatment for chemotherapy-induced diarrhea in dogs.Both drugs are marketed in the U.S. by Future Pak under a licensing agreement. The waivers reduce fees associated with the existing products.<h2 class="st-heading-2">Jaguar Eyes 2027 Filing For Pediatric Intestinal Failure&nbsp;</h2>Jaguar is developing a powder formulation of Crofelemer, the active ingredient in Mytesi and Canalevia-CA1, for rare intestinal-failure disorders. Its lead target is microvillus inclusion disease (MVID), which can leave children dependent on intravenous nutrition and fluids. The company aims to file a new drug application for MVID in mid-2027 and is also pursuing short bowel syndrome.Earlier this month, Jaguar said all randomized children in its MVID trial would continue into a single-blind extension phase. The company also reported that one patient’s weekly need for intravenous support, adjusted for body weight, fell by up to 48% after more than 12 months of crofelemer treatment.&nbsp;On an August investor call, CEO Lisa Conte said: “We are now fully a rare disease GI company with 100% of our human development efforts sharply and strategically focused on our rare disease program.” She said Jaguar was seeking a development and commercialization partner for the intestinal-failure program.<h2 class="st-heading-2">How Jaguar Is Funding Its Rare-Disease Push</h2>Jaguar licensed U.S. commercialization of Mytesi and Canalevia-CA1 to Future Pak in January, receiving $16 million at closing and a further $2 million after satisfying conditions for a holdback payment. Jaguar still manufactures and supplies the products, while U.S. sales revenue from the two brands goes to Future Pak.The deal also changed how Jaguar’s sales appear in its results. Second-quarter net prescription product revenue was about $1.2 million, primarily from supplying Mytesi to Future Pak. Its net loss attributable to common stockholders widened to $12.7 million from $10.4 million a year earlier.<h2 class="st-heading-2">How Do Retail Traders Feel About JAGX?</h2>On Stocktwits, JAGX retail sentiment surged from ‘neutral’ a day earlier to a record 95 out of 100, placing it in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/jagx_ss_3f4ee0732f.png" alt="jagx ss.png" width="635" height="349"><figcaption>JAGX sentiment and message volume as of September 23 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Oruveek70/message/664879123">said</a>, “$JAGX no-one is entering today without a stop loss in place because the mm and 'predatory lenders like Mark Fife/toxic debt funds' are, imo, creating "exit liquidity" to dump the next wave of dilution on new bagholders (sec filings).”<stembedurl>https://stocktwits.com/Oruveek70/message/664879123</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Oruveek70/message/664878885">said</a>, “$JAGX the low float after multiple rs was the catalyst. Now the window of opportunity and just how high they choose to run it up before switching the atm on with a vengeance.”<stembedurl>https://stocktwits.com/Oruveek70/message/664878885</stembedurl>JAGX stock has plunged 93% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-ally-jason-calacanis-bets-4-autonomy-stocks-bought-2-years-double-money/cZMEVQ4RB7w">Elon Musk Ally Jason Calacanis Bets These 4 Autonomy Stocks Will Be Bought Within 2 Years — And Double His Money&nbsp;</a>

In this photo illustration, the Jaguar Health logo is seen displayed on the screen of a tablet computer. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Current Price	$0.4988
Prev Close	$0.5575
Open	$0.54
Dividend Yield	0.00%
50-Day Moving Average	$3.12
Beta	2.72
Avg. Volume	5.33M
PE Ratio	0.00

52-Week High	$551.25
52-Week Low	$0.45
Market Capitalization	$1.16M
EPS (Annual)	-$12,059.19
Price to Book	0.02
Revenue Per Employee	$244,914.89

Feed

News

Sentiment

Earnings

Fundamentals

Info

JAGX Fundamentals